Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 8.19
+0.24 (3.02%)
May 29, 2026, 4:00 PM EST
Knight Therapeutics Cash Flow Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 5.61 | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 |
Depreciation & Amortization | 61.18 | 56.57 | 53.11 | 50.4 | 62.62 | 47.92 |
Stock-Based Compensation | 8.48 | 8.11 | 1.86 | 2.33 | 1.89 | 3.05 |
Other Adjustments | 7.1 | 7.75 | -3.4 | 28.06 | 15.85 | -22.64 |
Changes in Other Operating Activities | -22.05 | 1.89 | -19.62 | -28.01 | -5.47 | 0.63 |
Operating Cash Flow | 105.98 | 68.96 | 36.28 | 35.94 | 45 | 44.62 |
Operating Cash Flow Growth | 1068.61% | 90.07% | 0.95% | -20.14% | 0.86% | - |
Capital Expenditures | -4.86 | -1.91 | -2.47 | -0.95 | -2.89 | -3.83 |
Sale of Property, Plant & Equipment | - | 0.03 | 0.1 | 1.92 | - | - |
Purchases of Intangible Assets | -32.61 | -31.79 | -29 | -9.01 | -22.93 | -220.35 |
Proceeds from Sale of Intangible Assets | 17 | - | - | - | - | - |
Purchases of Investments | -72.7 | -70.39 | -162.57 | -334.16 | -188.21 | -64.32 |
Proceeds from Sale of Investments | 106.45 | 138.98 | 210.91 | 371.54 | 150.95 | 183.23 |
Payments for Business Acquisitions | -110.08 | -110.08 | - | - | - | - |
Other Investing Activities | 2.54 | - | - | - | - | - |
Investing Cash Flow | -96.8 | -75.16 | 16.96 | 29.34 | -63.08 | -105.28 |
Long-Term Debt Issued | 110.26 | 112.07 | 3.47 | 4.8 | 51.78 | 9.42 |
Long-Term Debt Repaid | -96.95 | -87.2 | -17.61 | -19.97 | -17.54 | -20.6 |
Net Long-Term Debt Issued (Repaid) | 13.31 | 24.87 | -14.14 | -15.17 | 34.24 | -11.18 |
Issuance of Common Stock | 0.51 | 0.51 | 1 | 0.38 | 0.34 | 0.3 |
Repurchase of Common Stock | -11.24 | -6.35 | -8.87 | -53.48 | -30.07 | -64.42 |
Net Common Stock Issued (Repurchased) | -10.74 | -5.84 | -7.86 | -53.1 | -29.73 | -64.12 |
Other Financing Activities | -17.56 | -13.62 | -11.54 | -12.73 | -7.27 | -3.02 |
Financing Cash Flow | -11.2 | 5.41 | -33.54 | -81 | -2.76 | -78.31 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -2.08 | -2.86 | 1.64 | 2.8 | 6.55 | -4.66 |
Net Cash Flow | -2.03 | -0.8 | 19.7 | -15.72 | -20.84 | -138.97 |
Free Cash Flow | 101.12 | 67.05 | 33.81 | 34.99 | 42.12 | 40.79 |
Free Cash Flow Growth | 50.81% | 98.30% | -3.37% | -16.92% | 3.26% | - |
FCF Margin | 19.81% | 14.90% | 9.11% | 10.66% | 14.35% | 16.75% |
Free Cash Flow Per Share | 1.02 | 0.67 | 0.33 | 0.33 | 0.37 | 0.33 |
Levered Free Cash Flow | 53.19 | 76.05 | 21.21 | -10.57 | 58.62 | 17.86 |
Unlevered Free Cash Flow | 51.92 | 54.21 | 38.41 | 18.54 | 13.22 | 31.88 |